José A. Lozada-Costas, M.D., Hematology, Oncology

HEMATOLOGY / ONCOLOGY

Torre Medica Hospital Auxilio Mutuo
Ste. 401, Ponce de Leon Ave. #735
Hato Rey, P.R. 00917

787-296-8394
787-900-5661

jlozadamd@gmail.com

EDUCATION

  • High School
    Commonwealth High School, Hato Rey, PR 1987
  • Undergraduate
    Massachusetts Institute of Technology, Cambridge, MA – BS in Chemistry, 1991
  • Medical School
    University of Puerto Rico, San Juan, PR – MD, 1995
  • Internship
    Baylor College of Medicine, Houston, TX – Internal Medicine 1995-1996
  • Residency
    Baylor College of Medicine, Houston, TX – Internal Medicine 1996-1998
  • Fellowship
    University of Texas MD Anderson Cancer Center/Baylor College of Medicine, Houston, TX – Hematology and Medical Oncology, 1998-2001

WORK EXPERIENCE

  • Private practice since July 2001.
  • Current Office (sole proprietor):
    • Doral Bank Center Suite 503, 576 Cesar Gonzalez, San Juan, PR 00917
  • Hospital Affiliation: Auxilio Mutuo Hospital, San Juan, PR
  • Member of the Medical Faculty 2001-present
  • Chief, Hematology-Oncology Section 2014 – present
  • President, Cancer Committee 2014 to present

LICENSURE

Texas, 1997 (#K2356)
Puerto Rico, 2001 (#13,841)

BOARD CERTIFICATIONS

  • United States Medical Licensure Examinations: Completed 12/1995
  • American Board of Internal Medicine: Internal Medicine 9/1998, recertified 4/2010
  • American Board of Internal Medicine: Hematology 11/2001, recertified 11/2010
  • American Board of Internal Medicine: Medical Oncology 11/2001, recertified 11/2010

ACADEMIC APPOINTMENTS

  • Clinical Instructor in Internal Medicine, University of Texas MD Anderson Cancer Center
    1999-2001
  • Assistant Professor of Medicine – ad honorem, University of Puerto Rico School of Medicine
    3/2010-present

PROFESSIONAL SOCIETIES

  • American College of Physicians – Fellow since 2011
  • Governor, Puerto Rico Chapter 2014-2018
  • American Society of Hematology – Member
  • American Society of Clinical Oncology – Member
  • Puerto Rico Association of Hematology and Medical Oncology — Member
  • President Oct 2009 – Oct 2011

HONORS/AWARDS

  • National Merit Scholarship – MIT, 1987-88
  • Phi Lambda Upsilon Honorary Chemical Society – MIT, 1990
  • Alpha Omega Alpha Honor Medical Society – UPR, 1995
  • Excellent Academic Achievement Award – UPR Medical Sciences Campus, 1995
  • Honor Student in Medicine – UPR School of Medicine, 1995
  • Certificate of Merit for Leadership – UPR Medical Sciences Campus, 1995
  • Recognition for Leadership – UPR School of Medicine, 1995
  • Henry D. McIntosh Award for Outstanding Resident in Medicine, Baylor College of Medicine, 1998
  • Chief Medical Oncology Fellow – University of Texas M.D. Anderson Cancer Center/Lyndon B. Johnson General Hospital, 2000-2001
  • American Society of Clinical Oncology Merit Award – 2001
  • Doctor’s Choice Award: 2003, 2005, 2006, 2007, 2012, 2013, 2014, 2015

PUBLICATIONS

  • Treatment of Adult Acute Lymphocytic Leukemia with Hyper-CVAD – Experience in a County Teaching Hospital. (Abstract) Blood Vol. 96, no. 11, Nov 16 2000.
  • Effects of Pregnancy following Treatment for Breast Cancer on Survival and Risk of Recurrence (Abstract with poster presentation). Proceedings of the American Society of Clinical Oncology Annual Meeting – May 2001.
  • A Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small Cell Lung Cancer as Front-Line and Second-Line Therapy. (Abstract). Proceedings of the American Society of Clinical Oncology Annual Meeting – May 2001.
  • Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer, United States; Vol 100, No. 3 (Feb 1, 2004): pp.465-9.

CLINICAL RESEARCH

  • PMA112509: “Dose-Ranging Phase I/II Study of Eltrombopag in Patients with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)”. GlaxoSmithKline. ( Sub-Principal Investigator) 2011.
  • Protocol CA225-346: Cisplatin and Vinorelbine in Combination with Cetuximab as First Line Treatment for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Single Arm Multicenter Safety Phase 2. (Sub-Principal Investigator) 2011.
Victor P. Carlo Vargas, M.D., FCAP
Alejandro Hidalgo, M.D.
Menu